Diabetes is not one disease. It is a family of metabolic conditions united by a single measurable consequence — chronically elevated blood glucose — but driven by fundamentally different mechanisms, requiring different treatments, and carrying different long-term implications depending on which type a person has.
The WHO estimates 422 million people worldwide currently have diabetes.
Approximately half are undiagnosed — living with blood glucose levels high enough to damage blood vessels, nerves, kidneys, and eyes, without knowing it. Understanding the full picture of diabetes — from mechanism to symptoms to treatment — is among the most consequential health knowledge any adult can have.
What Diabetes Is — The Core Mechanism
Every cell in the human body uses glucose as its primary fuel. After a meal, glucose enters the bloodstream and the pancreas releases insulin — a hormone that acts as a key, unlocking cells to absorb glucose for energy or storage.
Diabetes occurs when this system fails in one of two ways:
Insufficient insulin production: The pancreas cannot produce enough insulin to manage blood glucose levels (Type 1 diabetes — the pancreas produces almost none; Type 2 — the pancreas produces some but not enough).
Insulin resistance: Cells throughout the body become resistant to insulin’s signal, requiring progressively more insulin to achieve the same effect. When the pancreas can no longer compensate, blood glucose rises (the primary mechanism in Type 2 diabetes).
In both cases, the result is the same: glucose accumulates in the bloodstream rather than entering cells, producing hyperglycemia that, sustained over time, damages virtually every organ system in the body.
The Four Types of Diabetes
Type 1 Diabetes
An autoimmune condition in which the immune system destroys the insulin-producing beta cells of the pancreas. Without these cells, the body produces essentially no insulin. Type 1 diabetes requires lifelong insulin replacement — without it, the body turns to fat for fuel, producing ketones that accumulate to dangerous levels (diabetic ketoacidosis, or DKA).
Type 1 affects approximately 5 to 10% of all people with diabetes. It most commonly presents in childhood, adolescence, or young adulthood, though it can develop at any age. Its cause involves both genetic susceptibility and environmental triggers (viral infections, gut microbiome factors) that initiate the autoimmune attack.
Type 2 Diabetes
The most common form — approximately 90 to 95% of all diabetes cases. Type 2 develops when cells become resistant to insulin’s signal over years, and the pancreas progressively loses its capacity to compensate. It is strongly associated with excess weight (particularly visceral adiposity), physical inactivity, and dietary patterns high in refined carbohydrates and ultra-processed foods.
Unlike Type 1, Type 2 has a substantial prevention window. A prediabetes stage — where blood glucose is elevated but not yet at diabetic thresholds — precedes most Type 2 diagnoses, often for years. Lifestyle intervention during prediabetes reduces progression to diabetes by approximately 58% in clinical trials.
Gestational Diabetes
Develops during pregnancy in women who did not previously have diabetes. Placental hormones create insulin resistance that the pancreas cannot fully compensate in some women. It typically resolves after delivery but is a significant risk factor — women with gestational diabetes have approximately a 40 to 60% lifetime risk of subsequently developing Type 2 diabetes.
Other Specific Types
A smaller category covering diabetes caused by pancreatic disease or surgery, genetic defects in insulin secretion (MODY — maturity-onset diabetes of the young), prolonged corticosteroid use, Cushing’s syndrome, and several other identifiable causes. This category is frequently underrecognized — MODY in particular is commonly misclassified as Type 1 or Type 2, with implications for treatment.
Symptoms — What the Body Shows
The classic triad of diabetes symptoms reflects the consequences of unmanaged hyperglycemia:
Polyuria (excessive urination): When blood glucose exceeds the kidney’s reabsorption threshold, glucose spills into the urine and draws water with it osmotically, producing large volumes of urine. Frequent nighttime urination is often the first noticed symptom.
Polydipsia (excessive thirst): Follows directly from the fluid lost through polyuria. Profound, persistent thirst that is not relieved by normal fluid intake.
Polyphagia (excessive hunger): Cells starved of glucose (because insulin cannot deliver it) continue signaling hunger despite food intake. More prominent in Type 1 and in poorly controlled Type 2.
Additional symptoms that frequently precede diagnosis:
| Symptom | Mechanism |
|---|---|
| Unexplained weight loss | Glucose not absorbed; body catabolizes muscle and fat (more pronounced in Type 1) |
| Chronic fatigue | Cells energy-deprived despite elevated blood glucose |
| Blurred vision | High glucose changes lens fluid osmolarity, altering focal length |
| Slow-healing wounds | Impaired immune function and circulation reduce healing capacity |
| Recurrent infections | High glucose promotes bacterial and fungal growth; immune function impaired |
| Tingling or numbness in hands/feet | Early diabetic neuropathy from nerve damage |
| Dark patches of skin (acanthosis nigricans) | Associated with insulin resistance; appears in skin folds, neck, armpits |
Type 2 diabetes frequently produces no symptoms in its early stages. Diagnosis occurs incidentally on blood work in a large proportion of cases — which is why screening beginning at age 35 (or earlier with risk factors) is recommended for all adults.
Diagnosis
Four tests can diagnose diabetes. Confirmation typically requires either two abnormal results on the same test on separate days, or two different abnormal tests on the same day.
| Test | Normal | Prediabetes | Diabetes |
|---|---|---|---|
| Fasting glucose | <100 mg/dL | 100–125 mg/dL | ≥126 mg/dL |
| 2-hour OGTT | <140 mg/dL | 140–199 mg/dL | ≥200 mg/dL |
| HbA1c | <5.7% | 5.7–6.4% | ≥6.5% |
| Random glucose | — | — | ≥200 mg/dL with symptoms |
Treatment — By Type
Type 1 Diabetes
Insulin replacement is non-negotiable. Without it, Type 1 is fatal. Treatment has advanced substantially:
Multiple daily injections (MDI): Basal insulin (long-acting, once or twice daily) plus bolus insulin (fast-acting, before meals) approximates normal pancreatic insulin delivery. Doses are calculated based on carbohydrate content of meals, pre-meal blood glucose, and anticipated activity.
Insulin pumps (continuous subcutaneous insulin infusion): Deliver programmed basal insulin continuously through a small catheter, with user-triggered meal boluses. Hybrid closed-loop systems (artificial pancreas technology) use continuous glucose monitors (CGMs) to automatically adjust insulin delivery in real time, dramatically reducing both hypoglycemia and hyperglycemia.
Continuous glucose monitoring (CGM): Sensors worn on the arm or abdomen measure interstitial glucose every 1 to 5 minutes, providing trend data that fingerstick testing cannot. CGM use is now standard of care for Type 1 diabetes management.
Type 2 Diabetes
Treatment is stepwise and personalizes to the individual’s glucose levels, comorbidities, and preferences:
Step 1 — Lifestyle intervention: Weight loss of 5 to 10% of body weight, 150 minutes of moderate aerobic exercise per week, and a dietary pattern reducing refined carbohydrates and ultra-processed foods. In early Type 2, lifestyle change alone can achieve normal glucose levels.
Step 2 — Metformin: The foundational first-line medication. Reduces hepatic glucose production and improves insulin sensitivity. Decades of evidence support its safety, efficacy, and cardiovascular neutrality. Used in most Type 2 patients without contraindications.
Step 3 — Additional oral agents: Depending on cardiovascular risk, kidney function, weight considerations, and glucose levels: SGLT2 inhibitors (empagliflozin, dapagliflozin — also reduce cardiovascular and kidney disease risk), DPP-4 inhibitors, sulfonylureas.
Step 4 — GLP-1 receptor agonists: Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) — injectable medications with the strongest weight loss and HbA1c reduction of any non-insulin agents. Increasingly used earlier in treatment due to cardiovascular and renal outcome data.
Step 5 — Insulin: When oral agents and injectables cannot achieve target HbA1c, insulin therapy is added — beginning with basal insulin and progressing to basal-bolus regimens as needed.
Gestational Diabetes
Managed first with dietary modification and regular blood glucose monitoring. If glucose targets are not achieved within one to two weeks, insulin is added — oral agents (metformin, glyburide) are used in some settings but evidence for insulin is most robust.
Long-Term Complications — What Uncontrolled Glucose Does Over Time
The damage from chronically elevated blood glucose is cumulative and affects multiple systems:
Microvascular (small vessels):
- Diabetic retinopathy — leading cause of new blindness in working-age adults worldwide
- Diabetic nephropathy — leading cause of kidney failure requiring dialysis
- Peripheral neuropathy — pain, numbness, foot ulcers, risk of amputation
Macrovascular (large vessels):
- Cardiovascular disease — people with diabetes have 2 to 4 times the cardiovascular event risk of those without
- Stroke
- Peripheral artery disease
Every 1% reduction in HbA1c reduces the risk of microvascular complications by approximately 37% and myocardial infarction by 14%. The numbers that appear on a lab report are directly connected to the complications that develop or do not develop over the following decade.
This article is for informational purposes only and does not replace professional medical advice. Diabetes diagnosis, type classification, and treatment require evaluation by a qualified endocrinologist or physician. If you have symptoms consistent with diabetes or a family history of the condition, consult a healthcare provider for appropriate testing.
